HomeAI · summaries
Storia in 4 fonti
IL-33 Inhibitor Delivers in COPD Trials
Tozorakimab highly promising as biologic therapy in replicate phase III trials
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
abcnews.com
New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show
A new drug shows promise in reducing the symptoms of COPD, one of the top 10 leading cause of death in the U.S., according to the CDC.
- ·
iltempo.it
Farmaci, Bpco: tozorakimab riduce riacutizzazioni in 2 studi di fase 3
Milano, 9 set. (Adnkronos Salute) - I risultati completi degli studi di fase 3 Oberon e Titania hanno mostrato che tozorakimab, anticorpo monoclonale ...
